AIM ImmunoTech Inc.

In addition, we have a Code of Ethics and Business Conduct for Officers, Directors, Employees, Agents and Consultants (the “Code of Ethics”) that applies to all our employees (including our executive officers), our directors, agents, and consultants. The Code of Ethics is posted under “Corporate Governance” in the Investors section of our website athttps://aimimmuno.com/corporate-governance. We will disclose under “Corporate Governance” in the Investors section of our website any amendments to, or any waivers under, the Code of Ethics that are required to be disclosed by the rules of the SEC. On an annual basis, the Code of Ethics is reviewed and signed by each officer, director, employee, and strategic consultant.

Our Code of Ethics contains policies and procedures governing the purchase, sale, and/or other dispositions of the Company’s securities by directors, officers and employees that are reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to the Company.

You may obtain a copy of this Code of Ethics by visiting our website athttps://www.aimimmuno.com in the “Investors” tab under “Corporate Governance” or by written request to our office at 2117 SW Highway 484, Ocala, FL 34473.

Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

From time to time, we grant stock options to our employees, including our named executive officers. Historically, we have granted new-hire equity awards, which often include stock options, on or soon after a new hire’s employment start date and annual awards, which often include stock options, generally in the first quarter of each fiscal year, which annual grants are typically approved at a regularly scheduled meeting of the Compensation Committee occurring in such quarter. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the Board and at the time of each annual meeting of our stockholders, respectively, pursuant to the Non-Employee Director Compensation Policy, as further described under the heading, “Director Compensation” below. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features.

We donot grant equity awards in anticipation of the release of material nonpublic information, or MNPI, and we donot time the release of MNPI based on equity award grant dates or for the purposes of affecting the value of executive compensation. During 2025, we did not grant any stock options to our named executive officers. We have no information to disclose pursuant to Item 402(x)(2) of Regulation S-K.

We donot have a policy that prohibits employees (including officers) and directors or any of their designees, from purchasing financial instruments (including prepaid variable forward contracts, equity swaps, collars, and exchange funds), or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset, any decrease in the market value of the Company’s equity securities granted to the employee or director by the Company as part of the compensation of the employee or director or otherwise held, directly or indirectly, by the employee or director.